PHIO logo

PHIO PHARMACEUTICALS CORP

PHIONASDAQ
🏆 #4814 by market capEarnings Nov 11US Equity
$0.89▲ $0.04 (+4.55%)
Market closed · at close
🔔
Track PHIO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.5%
7d▲ 1.1%
14d▼ 4.2%
30d▼ 13.6%
ytd▼ 14.4%
1y▼ 56.6%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
74.2x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.89 – $0.89
52-Week Range
$0.81 – $4.19
Volume (shares)
100
Avg Volume (shares)
—
Shares Outstanding
11.6M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
74.2x
EPS (TTM)
$-1.39
Dividend Yield
—
Dilution (1yr)
+1375.3%
PHIO logo

PHIO PHARMACEUTICALS CORP

PHIO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +24.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▲ +12.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.6M▲ +1375.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$21M▲ +$16M YoY
StockOtter · stockotter.space

About PHIO PHARMACEUTICALS CORP

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.